Pharmaceutic adjuvant with collaborative work and anti-tumor application thereof

A technology for excipients and pharmaceutical compounds, applied in the field of pharmaceutical preparations, can solve the problems of loss of drug adaptability, no reported particle anti-tumor effect, low synthesis efficiency, etc., and achieve the effects of reducing treatment costs, good drug adaptability, and reducing toxic and side effects.

Active Publication Date: 2013-05-29
SUZHOU YOULIN BIO TECH
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent 20121002970.5 discloses covalently bonded folic acid-dextran-iron oxide nanoparticles, which have an in vitro targeting effect. It has not reported the anti-tumor effect of this particle itself (actually basically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutic adjuvant with collaborative work and anti-tumor application thereof
  • Pharmaceutic adjuvant with collaborative work and anti-tumor application thereof
  • Pharmaceutic adjuvant with collaborative work and anti-tumor application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Preparation of folic acid-dextran conjugates

[0047] 1. Synthesis of Succinylated Dextran

[0048] The synthetic route is as follows:

[0049]

[0050] Take 10.0g dextran (average molecular weight 20KDa, Mw / Mn=1.3, available from Shanghai Sunshine Reagent Co., Ltd.) and dissolve it in anhydrous dimethylformamide (DMF), stir for 20 minutes to form a clear solution, and then add 1670 mg succinic anhydride and 200.0 mg 4-dimethylaminopyridine (DMAP), stir rapidly until all solids dissolve. Place at room temperature (25°C) to allow the entire reaction solution to react for 24 hours, then put the reaction solution into a Spectra / Por3 dialysis bag (molecular weight cut-off 3,500) and dialyze in water for 2 days. The solution in the dialysis bag was then freeze-dried to obtain white succinylated dextran. Nuclear magnetic resonance (NMR) results are as follows: 1H-NMR (d-DMSO): 2.8 (-CH 2 CH 2 -, succinylated dextran), 3.2-3.6 (dextran), 4.4-5.8 (dextran). ...

Embodiment 2

[0060] Example 2: Preparation and Stability Test of Freeze-dried Powder Injection of Paclitaxel Encapsulated by Folic Acid-Dextran Conjugate

[0061] Take 1000 mg of the folic acid-dextran conjugate prepared in Example 1 and dissolve it in 100 ml of 15 mM phosphate buffer (pH=7.4). After dissolving, place it on a magnetic stirrer and stir at 400 rpm. During the stirring process, dissolve 250 mg of paclitaxel in 5 mL of ethanol, add it dropwise to the stirred solution, and place it in a FS-1 high-speed homogenizer (available from Jintan Zhongzheng Instrument Manufacturing Co., Ltd.) , Homogenize 6 times at maximum power, 1 minute each time, stop for 2 minutes, then put the homogenate into Spectra / Por3 dialysis bag (molecular weight cut off 3,500), dialyze in 15mM phosphate buffer (pH=7.4) 12 hours to remove ethanol, then add 2500mg mannitol to adjust the osmotic pressure, and pass through a 0.2μm membrane filter to sterilize. After being detected by a particle size tester, the...

Embodiment 3

[0065] Example 3: Pharmacodynamic study of paclitaxel freeze-dried powder injection coated with folic acid-dextran conjugate

[0066] The tumor cytotoxicity test was carried out on the freeze-dried powder injection prepared in Example 2, and the tested cells were human non-lobular lung cancer cells. Freeze-dried powder injections of different concentrations were added to the IC50 was calculated after 72 hours of treatment in cell culture medium. The results showed that the cytotoxicity of paclitaxel encapsulated by various concentrations of folic acid-dextran conjugates was similar to that of paclitaxel at the same concentration without any treatment. The cytotoxicity of the glycoconjugate itself is very small, IC50>0.05mg / ml, it can be seen that the cytotoxicity in vitro mainly comes from paclitaxel, and the folic acid-dextran conjugate basically does not affect the cytotoxicity of paclitaxel.

[0067] The freeze-dried powder injection prepared by Example 2 using different...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for packing a drug compound. The method comprises the steps of synthetic succinylation of glucosan; synthetic amination of folacin analogue; synthesis of folacin-glucan conjugate; mixing of the drug compound into the folacin-glucan conjugate; and then adding of pharmaceutically acceptable auxiliary material and/or material to dry. A preparation method of an auxiliary material for packing the drug compound, produced auxiliary material, further application of the auxiliary material and the like are also disclosed by the invention.

Description

technical field [0001] The present invention belongs to the field of pharmaceutical preparations. Specifically, the present invention relates to a method for encapsulating a pharmaceutical compound (such as paclitaxel). In addition to improving the physical and chemical properties of the drug, it can even act synergistically and improve the tolerance of the drug. In addition, the present invention also relates to the auxiliary material used in the method and the obtained medicine and the like. Background technique [0002] Most anticancer drugs currently used clinically, such as paclitaxel, Docetaxel (docetaxel), doxorubicin, etc., have poor solubility in normal saline and cannot be used directly in clinical practice, and some excipients are needed. E.g, Paclitaxel was formulated with a mixture of polyoxyethylene castor oil and ethanol, (Taxotere) is formulated with polysorbate and ethanol, but both cause strong side effects, such as allergic reactions, nephrotoxicity, n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/36A61K31/337C08B37/02A61P35/00
Inventor 李军游绍进陈琼
Owner SUZHOU YOULIN BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap